Colitis ulcerosa

In the pathogenesis of many chronic inflammatory diseases (e.g., rheumatoid arthritis, glomerulonephritis, colitis ulcerosa, Morbus Crohn, atopic dermatitis, psoriasis) autoimmune processes play an important role, too. Although first of all nonsteroidal antiinflammatory agents or glucocorticoids should be applied, immunosuppressive agents may also be indicated. 

Release of larger amounts of macrophage inhibitory factor (MIF) by homogeneous suspensions of DCs isolated from patients with colitis ulcerosa, due to the effect of Thl lymphocyte cytokines, in comparison with healthy human DC. It was observed that in an in vitro test MIF blocks the flow of mononuclear cells and granulocytes, while in in vivo it is released not only by lymphocytes but also by dendritic cells and leads to cell accumulation— occurrence of inflammatory infiltration. Disease development is also the result of the effect of TNFa, IL 1, IL 6, IL 8, and other cytokines released by macrophages and lymphocytes (Murakami et al., 2002). Thus, it has been proved that DCs can release MIF. 

Isenberg JI, Goldstein H, Korn AR, Ozeran RS, Rosen V (1968) Pulmonary vasculitis - an uncommon complication of ulcerative colitis. N Engl J Med 279 1376-1377 Jaup H (1978) Salazosulfapyridin-induziertes Lupus-erythematodes-Syndrom bei Colitis ulcerosa. Dtsch Med Wochenschr 103 1211-1213 Kandil E (1969) Fixed drug eruptions. Dermatologica 139 37... 

Miller B (1977) Wirkung und Nebenwirkungen der Therapie mit Salizylazosulfapyridin. In Kremer K, Kivelitz H (eds) Colitis ulcerosa. Thieme, Stuttgart, pp 71-86... 

---